ADVERTISEMENT
around your throat.
“What does she have?”
Marisol looked toward the pharmacy counter, then back at you.
“A rare enzyme disorder,” she said. “It’s called Alder-Kass Syndrome.”
The world narrowed.
You knew that name.
Of course you knew that name.
Ashford Global manufactured the leading treatment.
Veylora.
Your drug.
Your price.
Your boardroom crisis.
Your $480,000-a-year continue reading …
ADVERTISEMENT